Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data QTREX Quantum Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0.29
Cost of revenue
0
0
0.29
Gross profit
0
0
0
Research and development
4.07
8.18
7.32
6.32
7.5
Selling and marketing
1.98
1.33
0.75
0.75
0.59
General and administrative
6.94
5.38
4.06
4.19
5.53
Operating income
1.27
6.27
-13
-14.9
-12.1
-11.3
-13.6
Interest expense
1.16
Other non-operating income
-4.23
-0.28
0.53
0.04
0.34
Pre-tax income
4.58
7.23
-17.2
-15
-11.3
-11.1
-13.2
Income tax
0
0
0
Income from continuing operations
4.58
7.23
17
10.3
Net income
-4.58
16.9
-17.2
-15
-11.3
-11.1
-13.2
EBITDA
-12.9
-14.8
-12
-11.1
-13.5
EPS, basic
-2.40
-3.67
-3.24
-1.39
-0.93
-0.60
-0.45
EPS, diluted
-2.40
-3.67
-3.24
-1.39
-0.93
-0.60
-0.45
Shares, basic (weighted)
5.31
10.8
12.1
18.5
29.6
Shares, diluted (weighted)
5.31
10.8
12.1
18.5
29.6
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.1
0.54
23.9
6.78
5.04
5.11
3.16
Short-term investments
7.1
2.3
0.7
Inventory
0.44
0.74
Other current assets
0.59
0.43
0.59
0.52
Total current assets
0.68
24.5
14.5
7.79
6.81
4.41
Property, plant and equipment
0.05
0.2
0.41
0.51
0.5
0.45
Lease right-of-use assets
1.18
1.26
1.01
0.76
0.48
Other non-current assets
1.26
0.93
Total assets
0.99
25.9
16.2
9.31
8.07
5.34
Accounts payable
0
0.09
0.15
0.2
0.15
0.11
Accrued liabilities
0.07
0.08
Total current liabilities
0.95
4.31
1.66
2.98
3.37
2.82
Lease liabilities
0.1
0.9
0.87
0.59
0.38
0.19
Total liabilities
2.69
5.52
3.34
3.57
3.75
3.02
Paid-in capital
10.8
48.9
57.9
61.3
70.9
82.1
Retained earnings
-11.8
-28.8
-39.1
Other comprehensive income
-44.2
-55.5
-66.6
-79.8
Shareholders' equity
-1.33
23.7
13.6
5.74
4.32
2.32
Total equity
-4.64
-1.7
20.4
12.8
5.74
4.32
2.32
Total liabilities and equity
0.99
25.9
16.2
9.31
8.07
5.34
Shares outstanding
11.3
15.7
24.3
35.9
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-4.58
-7.23
-17.2
-15
-11.3
-11.1
-13.2
Depreciation and amortization
0.03
0.05
0.11
0.17
0.15
Stock-based compensation
6.7
4.88
1.43
1.89
3.58
Change in inventory
0
-0.44
-0.29
Cash from operations
-1.11
-1.88
-6.69
-9.21
-9.69
-9.37
-9.86
Capital expenditures
-0.03
-0.02
-0.18
-0.26
-0.21
-0.16
-0.1
Acquisitions
-16
Purchases of investments
-7.12
Cash from investing
-0.07
-0.03
-0.18
-7.38
4.59
1.49
0.57
Debt issued
0.31
0.03
Stock issued
14.3
0.03
0
4.65
Dividends paid
-0.09
-0.18
-0.2
-0.4
Cash from financing
1.27
2.29
30.2
-0.4
3.45
7.9
7.33
Exchange rate effect
0
0.01
0.95
-0.44
-0.07
0.06
0.03
Net change in cash
0.09
0.39
23.3
-16.6
-1.64
0.02
-1.97
Free cash flow
-1.14
-1.9
-6.87
-9.47
-9.9
-9.54
-9.96
Interest paid
0.03
0.11
0.09
0.07
0.07
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.78 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
0.7%
Gross profit / revenue.
Operating margin
-4,714.0%
Operating income / revenue.
EBITDA margin
-4,662.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-4,574.0%
Pre-tax income / revenue.
Net margin
-4,574.0%
Net income / revenue.
FCF margin
-3,448.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-3,412.0%
Cash from operations / revenue.
Return on equity (ROE)
-397.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-197.2%
Net income / average total assets.
R&D / revenue
2,594.0%
Research and development expense / revenue.
Stock-based pay / revenue
1,237.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
35.6%
Capital expenditures / revenue.
D&A / revenue
51.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-46.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-44.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-33.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-30.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
40.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
60.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
40.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.56x
Current assets / current liabilities.
Quick ratio
1.12x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.12x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.45
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.01
Revenue / diluted weighted shares.
FCF per share
-$0.34
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.33
Cash from operations / diluted weighted shares.
Book value per share
$0.06
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
150x
Market cap / revenue.
P/B
18.6x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
18.6x
Market cap / tangible book value, when positive.
EV/Sales
139x
Enterprise value / revenue.
FCF yield
-23.0%
Free cash flow / market cap.
Earnings yield
-30.6%
Net income / market cap (the inverse of P/E).
What was QTREX Quantum Ltd.'s revenue in fiscal 2025?
QTREX Quantum Ltd. reported revenue of $289.0K for fiscal 2025.
Was QTREX Quantum Ltd. profitable in fiscal 2025?
No. It reported a net loss of $13.2M.
How much free cash flow did QTREX Quantum Ltd. generate in fiscal 2025?
Cash from operations of $9.9M minus capital expenditures of $103.0K left free cash flow of -$10.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.